Williamson J, Atta H R, Kennedy P A, Muir J G
Br J Ophthalmol. 1985 Jan;69(1):38-40. doi: 10.1136/bjo.69.1.38.
Forty six normal volunteers were randomly assigned in double-blind fashion to once daily orally administered nadolol 10, 20, 40, or 80 mg for five days. Significant and dose related intraocular pressure (IOP) reductions (range 20-40%) were demonstrated both at three hours and 24 hours post dosing (p less than 0.001, all dosages). The reductions in IOP were dose related (p less than 0.05). One subject (in the 10 mg group) failed to show a significant intraocular pressure reduction. Significant reductions in blood pressure and heart rate also were recorded at all dose levels (with the exception of diastolic pressure in the 10 mg group), though considerably less in degree than IOP reductions. Two subjects (20 mg and 80 mg groups) experienced known side effects of beta blocker therapy necessitating termination of the drug, and four others experienced mild side effects but had no difficulty completing the study. The results have prompted further investigation of the usefulness of low doses of oral nadolol as therapy in chronic simple glaucoma patients.
46名正常志愿者以双盲方式被随机分配，每天口服一次纳多洛尔，剂量分别为10毫克、20毫克、40毫克或80毫克，持续五天。给药后三小时和24小时均显示出显著且与剂量相关的眼压（IOP）降低（降幅在20%至40%之间）（所有剂量组，p<0.001）。眼压降低与剂量相关（p<0.05）。一名受试者（10毫克组）未显示出显著的眼压降低。所有剂量水平均记录到血压和心率显著降低（10毫克组的舒张压除外），尽管降幅程度远小于眼压降低。两名受试者（20毫克和80毫克组）出现了β受体阻滞剂治疗的已知副作用，需要停药，另外四名受试者出现了轻微副作用，但完成研究没有困难。这些结果促使人们进一步研究低剂量口服纳多洛尔作为慢性单纯性青光眼患者治疗方法的有效性。
